Cache Test Div
top new

Hervorragende Patientenergebnisse

Orsiro wurde 2011 ins Leben gerufen und verfügt über ein umfangreiches klinisches Programm mit mehr als 48.500 eingeschlossenen Patienten. Orsiro Mission verwendet das klinisch erprobte Orsiro DES für ein völlig neues Liefersystem.

BIOFLOW-V (n = 1,334) FDA pivotal trial at 36 months

Continued and diverging significant differences compared to Xience2,3,4,5,6

BIOFLOW-V: FDA pivotal trial at 36 months

BIOFLOW-V: FDA pivotal trial at 36 months

40%

lower TLF rate6 ф

[p=0.003]

46%

lower TV - MI rate6 ф

[p=0.004]

52%

lower Iscemia-driven TLR rate6 ф

[p=0.008]

See BIOFLOW-V

TLF – Target Lesion Failure; TV-MI – Target Vessel Myocardial Infarction; TLR – Target Lesion Revascularization.
*compared to Xience in BIOFLOW-V, based on three consecutive years.
¤p-values for 36-m frequentist analysis of BIOFLOW-V6
фvs. Xience, based on 36-m frequentist analysis of BIOFLOW-V6

1. BIOTRONIK data on file, status January 2020; 2. Kandzari D et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017. 390(10105):1843-1852; 3. Kandzari D, et al. BIOFLOW-V: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions Science. Presentation at ESC 2017; 4. Kandzari D et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents. JACC. 2018. 72(25):3287-97; 5. Kandzari D et al. Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization: 3-year outcomes from the randomized BIOFLOW V trial. JACC: Cardiovascular Interventions. 2020, doi: 10.1016/j. jcin.2020.02.019; 6. Kandzari D et al. D et al. Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization: 3-year outcomes from the randomized BIOFLOW V trial. JACC: Cardiovascular Interventions. 2020. Supplementary material.

Xience, Xience Prime and Xience Xpedition are trademarks or registered trademarks of the Abbott Group of Companies.
Orsiro is a trademark or registered trademark of the BIOTRONIK Group of Companies.